Med-Chemist : "Quintessential Medicinal Chemistry"
Showing posts with label
ESR1 Mutations
.
Show all posts
Showing posts with label
ESR1 Mutations
.
Show all posts
Thursday, February 29, 2024
FDA Approves Orserdu (elacestrant) for Patients with ESR1 Mutations in ER+, HER2- Advanced or Metastatic Breast Cancer
›
The Menarini Group (“Menarini”), a leading Italian pharmaceutical and diagnostics company, announced the U.S. Food and Drug Administration ...
›
Home
View web version
